Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Other Non-current Assets
Long-term assets not reported separately.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets remains negative
Q1 FY2026 other non-current assets was $0, compared with $0 a year earlier.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 4.34M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Assets vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 other non-current assets of $0 is the lowest of the 6 companies compared; the peer median is $313.89K.
- Other non-current assets amounts to 0.0% of total assets for TELO, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.57M | +388.0% | -59.8% | 0.8% | |
| Mar 2026 | $683K | +1293.9% | +150.2% | 2.6% | |
| Mar 2026 | $313.89K | -75.9% | +130.2% | 1.6% | |
| Mar 2026 | $267K | -84.1% | -25.0% | 0.2% | |
| Mar 2026 | $27K | +2700100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TELO) | $313.89K | +388.0% | +52.6% | 0.8% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.